Research Repository
Technical articles for EU pharmaceutical professionals on peptide CDMO sourcing, preclinical workflows, and regulatory compliance.
A UK Biobank phenomic and Mendelian randomisation study links genetically lower GIP to reduced obesity and cardiovascular risk, published the same week as a review calling GIPR agonism versus antagonism the field's unsettled question.
A non-randomised Japanese cohort found 2.5 mg and 5 mg tirzepatide produced statistically indistinguishable weight loss at six months, with fewer adverse events at the lower dose — one of several late-July reports reframing where the dual agonist's dose ceiling sits.
A randomised protocol published in late July sets gradual semaglutide dose reduction over 16 weeks against abrupt cessation, with body weight change as the primary outcome — one of six semaglutide readouts landing in a single week.
A 50-participant phase 2 trial missed its primary craving endpoint but reduced heavy drinking days, drinks per drinking day and cannabis use days — one of several late-July GLP-1 readouts pushing the class past metabolic endpoints.
Registry entries and journal reports posted in late July 2026 put semaglutide into prostate cancer surgery and cognition studies, map where GIPR agonism and antagonism act in the brain, and document tirzepatide-specific hypersensitivity.
